High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma

Publisher： Karger

E-ISSN： 2296-5262|33|5|231-238

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.33, Iss.5, 2010-04, pp. : 231-238

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Afatinib, Erlotinib and Gefitinib in the First-Line Therapy of EGFR Mutation-Positive Lung Adenocarcinoma: A Review

By  

Oncology Research and Treatment, Vol. 36, Iss. 9, 2013-08 ,pp. : 510-518

Karger

Access to resources Recommend Favorite

Rapid Symptomatic Improvement in Gefitinib-Treated Patients with EGFR-Mutated Lung Cancer: Possible Role of Downregulation of Inflammatory Molecules?

By  

Oncology Research and Treatment, Vol. 34, Iss. 10, 2011-09 ,pp. : 559-560

Karger

Access to resources Recommend Favorite

EGFR-Mutated Breast Metastasis of Lung Adenocarcinoma: A Case Report

By  

Case Reports in Oncology, Vol. 8, Iss. 1, 2015-03 ,pp. : 164-168

Karger

Access to resources Recommend Favorite

Challenges in the Management of EGFR-Mutated Non-Small Cell Lung Cancer Patients with Acquired Resistance to Tyrosine Kinase Inhibitors

By  

Oncology, Vol. 87, Iss. 2, 2014-07 ,pp. : 83-94

Karger

Access to resources Recommend Favorite

First-Line Therapy of Mutated Non-Small Cell Lung Cancer: An Update

By  

Oncology Research and Treatment, Vol. 35, Iss. 5, 2012-04 ,pp. : 293-299

Karger

Access to resources Recommend Favorite